Clinical Trial Update: Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating intravenous bevacizumab for symptomatic cerebral arteriovenous malformations. The study focuses on efficacy and safety …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Arteriovenous Malformation

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Conditions: Cerebral AV Malformation | Phase 2, Phase 3 | Status: RECRUITING